Mortality After Home Hemodialysis Treatment Failure and Return to In-Center Hemodialysis.

End-stage kidney disease (ESKD) home hemodialysis (HHD) in-center hemodialysis (ICHD) modality change mortality treatment failure

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
01 2022
Historique:
received: 23 12 2019
accepted: 11 05 2021
pubmed: 19 7 2021
medline: 3 2 2022
entrez: 18 7 2021
Statut: ppublish

Résumé

Patients on home hemodialysis (HHD) may eventually return to in-center hemodialysis (ICHD) for clinical, technical, or psychosocial reasons. We studied the mortality of patients returning to ICHD after HHD, comparing it with the mortality experience among patients receiving HHD and patients receiving ICHD without prior treatment with HHD. Retrospective cohort study. All patients represented in the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) who commenced HD during 2005-2015 and were treated for >90 days. ICHD and/or HHD, and clinical characteristics at study entry. Mortality and cause of death. A time-varying multivariate Cox proportional hazards analysis with shared frailty was implemented to explore the association between patient treatment states and mortality. Patients were censored at the time of transplantation or change in treatment modality to peritoneal dialysis. A total of 19,306 patients initiated HD and were treated for >90 days. The mean age of patients was 60.8 ± 15.4 (SD) years, 62% were male, and 49% had diabetes. After HHD treatment failure, adjusted mortality was increased compared with continued HHD at 0-30 days (HR, 3.93 [95% CI, 2.09-7.40]; P < 0.001), 30-90 days (HR, 3.34 [95% CI, 1.98-5.62]; P < 0.001), and >90 days (HR, 2.29 [95% CI, 1.84-2.85]; P < 0.001). Covariates recorded at dialysis initiation, residual confounding underlying successful initiation of HHD treatment, and observational data lacking detail on cause of HHD treatment failure. HHD treatment failure is associated with a significant increase in mortality compared with continued HHD. This risk was present in both the early (first 30 days and 30-90 days) and late (>90 days) periods after HHD treatment failure. Further investigation into the specific causes of treatment failure and death may highlight specific high-risk patients.

Identifiants

pubmed: 34274359
pii: S0272-6386(21)00733-2
doi: 10.1053/j.ajkd.2021.05.021
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-23.e1

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

David J Semple (DJ)

Department of Renal Medicine, Auckland District Health Board, Auckland, New Zealand; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. Electronic address: dsemple@adhb.govt.nz.

Matthew Sypek (M)

ANZDATA Registry, SA Health and Medical Research Institute, Adelaide, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Shahid Ullah (S)

ANZDATA Registry, SA Health and Medical Research Institute, Adelaide, Australia; Adelaide Medical School, University of Adelaide, Adelaide, Australia; College of Medicine and Public Health, Flinders University, Adelaide, Australia.

Christopher Davies (C)

ANZDATA Registry, SA Health and Medical Research Institute, Adelaide, Australia; Adelaide Medical School, University of Adelaide, Adelaide, Australia.

Stephen McDonald (S)

ANZDATA Registry, SA Health and Medical Research Institute, Adelaide, Australia; Adelaide Medical School, University of Adelaide, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH